Table 2 Characteristics of treatment response.
Characteristics | Group A1 (n = 25) | Group B2 (n = 7) | All patients (n = 32) |
|---|---|---|---|
Median duration of follow-up (months) | 15 (n = 25) | 21 (n = 7) | 16 (n = 32) |
Median duration until VL below detection limit (days) | 52 (n = 24)* | - | 52 (n = 24)* |
Median increase in CD4+ T-cell count at month 3 | 112 cells/μl (n = 25) | 21 cells/μl (n = 7) | 141 cells/μl (n = 32) |
Median increase in CD4+ T-cell count at month 6 | 96 cells/μl (n = 25) | 88 cells/μl (n = 7) | 124 cells/μl (n = 32) |
Number of patients with VL below detection limit after 3 months | 18/25 | 6/7** | 24/32 |
Number of patients with sustained complete response (median duration of observation) | 12 (11.5 months) | 5 (14.2 months) | 17 (12.1 months) |
Number of patients with secondary treatment failure (median duration to failure) | 8 (9.2 months) | 2 (10 months) | 9 (9.2 months) |
Number of patients with partial response | 3 | 0 | 3 |
Number of patients with primary treatment failure (median duration to failure) | 2 (3.5 months) | - | 3 (4.0 months) |